Loading organizations...
Based in Medley, Florida, Entopsis is a biotechnology organization that develops and commercializes artificial intelligence-driven biomedical diagnostic solutions for oncology and various autoimmune conditions. The enterprise's primary technology platform, OpsisDx, facilitates the rapid detection of cancer and other diseases through proprietary, non-invasive urine analysis techniques. Operating within the multibillion-dollar global diagnostics market, the firm targets both individual patients and broader healthcare systems to address clinical testing requirements. Over its more than 14 years of continuous operation, the life sciences company has maintained strategic associations with the HudsonAlpha Institute for Biotechnology to advance its research and development initiatives. To support its clinical pipeline, the firm has secured early-stage grant funding from notable institutional backers, including Breakout Labs and the Thiel Foundation. Entopsis was officially founded in the year 2011 by founders Obdulio Piloto and Ian Cheong.
Entopsis has raised $800K across 1 funding round.
Entopsis has raised $800K in total across 1 funding round.
Entopsis has raised $800K in total across 1 funding round.
Entopsis's investors include Breakout Labs.
Entopsis has raised $800K across 1 funding round. Most recently, it raised $800K Seed in March 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 30, 2015 | $800K Seed | — | Breakout Labs | Announced |
